<DOC>
	<DOCNO>NCT02752516</DOCNO>
	<brief_summary>A Phase I Additional Study Anlotinib Tolerance Pharmacokinetics.To study pharmacokinetic characteristic Anlotinib human body , recommend reasonable regimen subsequent research .</brief_summary>
	<brief_title>A Phase I Additional Study Anlotinib Tolerance Pharmacokinetics</brief_title>
	<detailed_description />
	<criteria>Histological documentation Advanced solid tumor except digestive tract tumor , least one measurable lesion ( RECIST1.1 ) Lack standard treatment treatment failure 1865 year , ECOG PS:01 , Life expectancy 3 month 30 Days last cytotoxic therapy Main organs function normal Women childbearing potential agree use utilize adequate method contraception ( intrauterine device，contraceptive condom ) throughout treatment least 6 month study stopped；the result serum urine pregnancy test negative within 7 day prior study enrollment，and patient require nonlactating；Man participant agree use utilize adequate method contraception throughout treatment least 6 month study stop Patients participate study voluntarily sign informed consent Patients use anlotinib Patients factor could affect oral medication ( dysphagia，chronic diarrhea , intestinal obstruction etc . ) Brain metastasis patient symptom symptom control &lt; 3 month Patients severe and/or unable control diseases，including： 1 . Blood pressure unable control ideally ( systolic pressure≥150 mmHg，diastolic pressure≥100 mmHg ) ; 2 . Patients Grade 1 high myocardial ischemia , myocardial infarction malignant arrhythmia ( include QT≥480ms ) patient Grade 1 high congestive heart failure ( NYHA Classification ) ; 3 . Patients active unable control serious infection ; 4 . Patients cirrhosis , decompensated liver disease , active hepatitis ; 5 . Patients poorly control diabetes ( fast blood glucose ( FBG ) ＞10mmol/L ) 6 . Urine protein ≥ ++，and 24hour urinary protein excretion＞1.0 g confirm Patients nonhealing wound fracture Patients CTC AE Grade 1 high bleeding event occur lung CTC AE Grade 2 high bleeding event occur within 4 week prior assignment ; Patients physical sign bleed diathesis receive thrombolysis anticoagulation Patients drug abuse history unable get rid Patients mental disorder Patients participate anticancer drug clinical trial within 4 week History immunodeficiency Patients concomitant disease could seriously endanger safety could affect completion study accord investigator ' judgment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>